Utolsó frissítés :
18/04/2024
Szimpatomimetikum   Dexmedetomidine  
Injekció
Az oldatok stabilitása A keverékek stabilitása Stabilitást befolyásoló tényezők Kompatibilitás Az alkalmazás módja Irodalom Pdf
   Kémiai szerkezet   

Kereskedelmi név   Kereskedelmi név     

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Avemedit Mexikó
Danmidrat Mexikó
Demesynt Mexikó
Dexdine India
Dexdor Belgium, Franciaország, Izland, Norvégia, Románia, Spanyolország
Dexem India
Dexmedetomidina Chile, Colombia
Dexmetin Argentína, Chile
Dexodine Chile, Peru
Dextocris Chile
Dextomid India
Drimitec Mexikó
Eusedex Chile, Peru
Frelig Mexikó
Kmetodin Ecuador
Krunamina Mexikó
Precedex Amerikai Egyesült Államok, Argentína, Chile, Colombia, Ecuador, Egyesült Arab Emírségek, India, Kanada, Malaysia, Mexikó, Peru, Szaúd-Arábiában, új-Zéland, Venezuela
Preser Chile
Priaxim Ecuador
Valertropina Argentína
Xamdex India
Irodalom   Injekció   Irodalom : Dexmedetomidine  
Type Publikáció
1712 Napló Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
3152 Napló Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3299 Napló Anderson C.R, Mackay M.W, Holley M, Kay B.A
Stability of dexmedetomidine 4 µg/mL in polypropylene syringes.
Am J Health-Syst Pharm 2012 ; 69:595-597.
3372 Napló Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3433 Napló Preslaski C.R, Mueller S.W, Wempe M.F, Robert MacLaren R.
Stability of dexmedetomidine in polyvinyl chloride bags containing 0.9% sodium chloride injection.
Am J Health-Syst Pharm 2013 ; 70:1336-1341
3824 Napló Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Poszter Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poszter Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poszter So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3964 Napló Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4011 Napló Gersonde F, Eisend S, Haake N, Kunze T.
Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit.
EJHP 2016 2016;0:1-11
4029 Napló Marquis K, Hohlfelder B, Szumita Paul.
Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags.
Int J Pharm Compound 2017 ; 21, 5: 436-439
4055 Napló Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Napló Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Napló Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4357 Napló Campos-Baeta, Saavedra-Mitjans M, Garin N, Cardenete J, Cardona D, Riera P.
Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition.
Nutrition in clinical Practice 2020 ; 35: 967-972.
4389 Napló Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4433 Napló Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4434 Napló Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4491 Napló De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2020
4507 Napló Ross E, Salinas A, Petty K, Her C, Carpenter J.
Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528 Napló Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4538 Napló Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K.
Compatibility of pentoxifylline and parenteral medications.
Archives of Disease in Childhood 2020 ; 105: 395-397.
4545 Napló Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H.
Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment.
Journal of Nippon Medical school 2021
4569 Napló Lee T.M , Villareal C.L, Meyer L.M.
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Hosp Pharm 2021 ; 56, 4: 282-286.
4570 Napló Greenhill K, Hornsby E, Gorman G.
Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients.
Pharmaceuticals 2019
4603 Napló Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4651 Napló De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2021 ;180,1169–1176.
4655 Napló Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33
4723 Napló Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H
Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration.
Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742 Napló Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales